The artificial knockdown or inactivation of Nac1 leads to the apoptosis of Nac1-overexpressing ovarian cancer cells [7] and restores their sensitivity to chemotherapeutics [9], thereby validating this protein as a potential therapeutic target. The gene discussed is NACC1; the disease is ovarian carcinoma.